AstraZeneca PLC Director/PDMR Shareholding (1090G)

TIDMAZN

RNS Number : 1090G

AstraZeneca PLC

24 May 2017

24 May 2017 15:00 BST

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 23 May 2017, it was notified by Mark Mallon, a Person Discharging Managerial Responsibilities of the Company, that, on 23 May 2017, Mr Mallon sold 20,000 American Depositary Shares (ADSs). Two ADSs are equivalent to one ordinary share of $0.25 in the Company.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  --------------------------------------------------------------- 
 a)   Name                       Mark Mallon 
---  -------------------------  ------------------------------------ 
 2    Reason for the notification 
---  --------------------------------------------------------------- 
 a)   Position/status            Person Discharging Managerial 
                                  Responsibilities 
---  -------------------------  ------------------------------------ 
 b)   Initial notification       Initial notification 
       /Amendment 
---  -------------------------  ------------------------------------ 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  --------------------------------------------------------------- 
 a)   Name                       AstraZeneca PLC 
---  -------------------------  ------------------------------------ 
 b)   LEI                        PY6ZZQWO2IZFZC3IOL08 
---  -------------------------  ------------------------------------ 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  --------------------------------------------------------------- 
 a)   Description of             AstraZeneca PLC American 
       the financial              Depositary Shares 
       instrument, type 
       of instrument 
                                  CUSIP: 046353108 
       Identification 
       code 
---  -------------------------  ------------------------------------ 
 b)   Nature of the              Sale of AstraZeneca PLC American 
       transaction                Depositary Shares 
---  -------------------------  ------------------------------------ 
 c)   Price(s) and volume(s)       Price(s)         Volume(s) 
                                   ---------------  ---------- 
                                    US$ 33.900214    20,000 
                                   ---------------  ---------- 
---  -------------------------  ------------------------------------ 
 d)   Aggregated information     Not applicable - single transaction 
 
 
       - Aggregated volume 
 
 
       - Price 
---  -------------------------  ------------------------------------ 
 e)   Date of the transaction    23 May 2017 
---  -------------------------  ------------------------------------ 
 f)   Place of the transaction   NYSE 
---  -------------------------  ------------------------------------ 
 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Enquiries 
 Esra Erkal-Paler       UK/Global                                 [phone] 
 Karen Birmingham       UK/Global                                 [phone] 
 Rob Skelding           UK/Global                                 [phone] 
 Jacob Lund             Sweden                                    [phone] 
 Michele Meixell        US                                        [phone] 
 Investor Relations 
 Thomas Kudsk Larsen                                              [phone] 
 Craig Marks            Finance, Fixed Income, M&A                [phone] 
 Henry Wheeler          Oncology                                  [phone] 
 Mitchell Chan          Oncology                                  [phone] 
 Lindsey Trickett       Cardiovascular & Metabolic Diseases       [phone] 
 Nick Stone             Respiratory                               [phone] 
 Christer Gruvris       Autoimmunity, Neuroscience & Infection    [phone] 
 US toll free                                                     [phone] 
 

Adrian Kemp

Company Secretary, AstraZeneca PLC

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUSARRBVAVUAR

(END) Dow Jones Newswires

May 24, 2017 10:00 ET (14:00 GMT)